Skip to main content
Homepage of ProQR
  • We are ProQR
    • About ProQR Therapeutics
    • Founding story
    • Leadership
    • Contact
    • Events
  • Science & Pipeline
    • Science overview
    • Pipeline
    • Axiomer technology
      • How Axiomer and ADAR work
    • RNA therapy
    • Presentations & Publications
    • Partnerships
  • News
    • Press Releases
    • Blogs, stories and news
    • Email alerts
  • Careers
    • Working at ProQR
    • Vacancies
    • Recruitment Experience
  • Investors & Media
    • Investors & Media overview
    • Press Releases
    • Events
    • Corporate presentation
    • Corporate governance
    • Financials and filings
    • Stock info
    • Analyst coverage
    • Contact us
  1. Home
Listen

Unlocking the Potential of Innovative Editing Oligonucleotides (EONs) to Address Liver Originated Disorders

Presentation

Published on May 09, 2023 at TIDES USA

Link Download

Description

The Axiomer® platform uses editing oligonucleotides (EONs) to target specific RNA for A-to-I editing by recruiting endogenous Adenosine Deaminase Acting on RNA (ADAR). The therapeutic possibilities of this editing platform are not only limited to disease causing mutations and can potentially address high unmet medical needs by editing wild-type RNA to engineer proteins or modify their function as well as creating de novo mutations with the potential to prevent diseases. Through now further developed design principles there has been an established improvement of specificity and efficacity of EONs. The presentation reviews EONs structure activity, the potential of Axiomer platform as well as its applicability for the treatment of liver originated disorders.

Thumbnail of presentation Unlocking the potential of innovative EONs

Tags

  • TIDES USA
  • ADAR
  • RNA Editing
  • Axiomer

Share page

  • Facebook
  • Linkedin
  • Twitter
  • Whatsapp
  • Email

Related publications

  • Development of RNA Base Editing Technologies for Precision Medicines

    Development of RNA Base Editing Technologies for Precision Medicines with Axiomer® and Trident® presented at TIDES USA 2022 by Gerard Platenburg - ProQR Therapeutics.

    Date: May 11, 2022

    Presentation
  • Rational Design of RNA Editing Guide Strands: Cytidine Analogs at the Orphan Position

    Modification of a guide RNA can mimic the effect of hyperactive mutants and advance the approach of recruiting endogenous ADARs for site-directed RNA editing reported in Journal of the American Chemical Society (JACS) by Doherty EE et al.

    Date: May 12, 2021

    Author(s): Doherty EE, et al.

    Publication
  • Structure-based computational approach for optimizing oligonucleotides for A-to-I editing

    Applicability of a structure-based modelling approach as a tool for in silico screening of oligonucleotides for targeted RNA editing presented at Oligonucleotide Therapeutics Society (OTS) 2018 by Julien Boudet

    Date: September 30, 2018

    Author(s): J Boudet et al.

    Poster
  • Progress on Development of RNA Base Editing Technologies for Precision Medicines

    Progress on Development of RNA Base Editing Technologies for Precision Medicines, including Axiomer® platform presented at TIDES EU by Gerard Platenburg - ProQR Therapeutics

    Date: November 18, 2022

    Presentation
Internal link More publications

Follow us

  • Twitter (opens in new window)
  • Facebook (opens in new window)
  • Instagram (opens in new window)
  • Linkedin (opens in new window)
  • Youtube (opens in new window)
  • Soundcloud (opens in new window)
  • Contact
  • Disclaimer
  • Privacy
  • Sitemap

© 2025 ProQR Therapeutics. All Rights Reserved.

Back to top